LEQVIO is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is Inclisiran Sodium.
| Product ID | 0078-1000_171e003a-8f8e-402e-b79c-fbca7d057373 |
| NDC | 0078-1000 |
| Product Type | Human Prescription Drug |
| Proprietary Name | LEQVIO |
| Generic Name | Inclisiran |
| Dosage Form | Injection, Solution |
| Route of Administration | SUBCUTANEOUS |
| Marketing Start Date | 2021-12-22 |
| Marketing Category | NDA / |
| Application Number | NDA214012 |
| Labeler Name | Novartis Pharmaceuticals Corporation |
| Substance Name | INCLISIRAN SODIUM |
| Active Ingredient Strength | 284 mg/1.5mL |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
| Marketing Start Date | 2021-12-22 |
| NDC Exclude Flag | N |
| Sample Package? | N |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() LEQVIO 79238111 5640111 Live/Registered |
NOVARTIS AG 2018-05-30 |
![]() LEQVIO 79157840 4741480 Dead/Cancelled |
NOVARTIS AG 2014-11-11 |